Bicycle Therapeutics plc

NASDAQ:BCYC

Biotechnology

Healthcare
$3.11 -1.36%

-$0.06 today

Market cap
$217.99M
Beta
1.54
P/E (TTM)
-1.3
EPS (TTM)
-$3.14
52W Low $3.95High $9.18

Volume 0.57M

Average 0.49M

BCYC Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Bicycle Therapeutics plcNASDAQ: BCYC

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $60.83M (cash outflow) fell 0.3% year over year, behind the +7.2% change in trailing-twelve-month net income. Sequentially, it rose 205.3% from the prior quarter. Over 3 fiscal years it compounded at +24.8% a year.

Context

  • Net income amounted to 301.7% of revenue in FY2025, down 177.5 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of -$157.67M (-28.0%) for the fiscal year ending Dec 2026, a slowdown from the +29.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$60.83M+205.3% QoQ
Last fiscal yearDec 2025
-$218.96M+29.5% YoY
LTMMar 2026
-$218.8M+7.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.3%-49.0%-48.7 pp
1 year+29.5%-28.0%-57.5 pp
3-year CAGR+24.8%-2.9%-27.7 pp
5-year CAGR-14.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(218.96M) USD
Year-over-year change
-29.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BCYC compares with its peers on the latest reported figures

  • BCYC's LTM Mar 2026 net income of $218.8M is the 2nd largest of the 10 companies compared; the peer median is $136.99M.
  • Its year-over-year change of +7.2% is the 5th highest of 9, against a peer median of +7.4%.
  • Net income amounts to 344.6% of revenue for BCYC, versus a peer median of 177.7%.
BCYC Competitors Peer median
Net Income for BCYC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$222.39M -13.8%+21.9%—
BCYCBicycle Therapeutics plcLTM Mar 2026$218.8M +7.2%+24.8%344.6%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$160.9M -8.8%+9.2%182.3%
PRTAProthena Corporation plcLTM Mar 2026$151.18M +37.1%+27.8%260.9%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$138.44M ——119.4%
ADCTADC Therapeutics S.A.LTM Mar 2026$136.99M -8.6%-3.2%173.0%
OMEROmeros CorporationLTM Mar 2026$81.36M +148.9%-73.6%822.4%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$76.12M +14824.7%-12.0%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026$68.17M +23.5%+19.2%—
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$26.09M -85.3%-21.0%37.5%
Peer median (excluding BCYC) $136.99M+7.4%+3.0%177.7%

Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(66.82M)(112.72M)(180.66M)(169.03M)(218.96M)
Depreciation & Amortization1.41M3.69M6.55M7.17M6.42M
Deferred Income Tax(1.67M)(4.98M)3.31M(5.23M)(850K)
Stock-Based Compensation12.08M26.78M32.48M38.08M39.46M
Change in Working Capital38.07M672K76.66M(33.46M)(75.75M)
Accounts Receivables4.54M(11.35M)(1.2M)(11.95M)2.89M
Inventory(4.79M)0000
Accounts Payables1.2M2.56M8M3.1M(6.87M)
Other Working Capital37.12M9.46M69.86M(24.61M)(71.77M)
Other Non-Cash Items2.14M442K1.04M(2.26M)0
Operating Cash Flow(14.79M)(86.11M)(60.63M)(164.72M)(249.68M)
Capital Expenditures(2.03M)(18.99M)(2.93M)(1.24M)(2.36M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00005.49K
Investing Cash Flow(2.03M)(18.99M)(2.93M)(1.24M)(2.35M)
Debt Repayment15M00(31.91M)0
Common Stock Issued298.54M5.7M249.35M544.13M37.09K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.18M989K682K7.53M(168.09K)
Financing Cash Flow320.73M6.69M250.03M519.75M(131K)
Effect of Forex Changes(1.21M)(1.12M)1.35M(694K)804K
Net Change in Cash302.69M(99.53M)187.82M353.1M(251.35M)
Free Cash Flow(16.82M)(105.1M)(63.56M)(165.96M)(252.61M)

Bicycle Therapeutics plc

NASDAQ:BCYC

Intrinsic Alpha fair value

Locked

Current Price

$3.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.